前列腺癌患者血清PSA和PTHrP联合检测及临床价值

Clinical Significance of Simultaneous Assay of PSA and PTHrP in Prostatic Cancer Patients

目的：观察３１例前列腺癌患者血清ＰＳＡ与ＰＴＨｒＰ的关系。方法：用放射免疫分析法（ＲＩＡ）和免疫放射分析法（ＩＲＭＡ）。结果：１）正常组测得血清ＰＳＡ值为２．０±１．４４μｇ／Ｌ（ｘ±ｓ），血清ＰＴＨｒＰ（１～８６）值为１．６±０．６ｐｍｏｌ／Ｌ（ｘ±ｓ）。２）前列腺癌组测得血清ＰＳＡ值为８０±５２．５５μｇ／Ｌ（ｘ±ｓ），ＰＴＨｒＰ测得值为４．５８±４．４０ｐｍｏｌ／Ｌ（ｘ±ｓ），显著高于健康组（ｔ＝２．７４９，Ｐ＜０．０１和ｔ＝２．７５，Ｐ＜０．０１）。３）２１例伴发ＨＨＭ前列腺癌患者，ＰＴＨｒＰ（１～８６）升高的有１３例，占６１．９％（１３／２１），测得均值为７．４ｐｍｏｌ／Ｌ（２．８８～１９．１ｐｍｏｌ／Ｌ）。４）２１例伴发ＨＨＭ前列腺癌患者ＰＳＡ和ＰＴＨｒＰ浓度呈显著正相关（ｒ＝０．８２３，Ｐ＜０．０１）。

The relationship between serum level of prostate specific antigen (PSA) and parathyrin related protein (PTHrP) was analyzed in 31 patients with prostatic cancer. The results showed: 1) the serum PSA and PTHrP (1～86) values in healthy subjects were 2.0±1.44 μg/L x±s and 1.6±0.6 pmol/L (x±s) respectively; 2) the serum PSA and PTHrP values in prostatic cancer were 80±52.55μg/L x±s and 4.58±4.40pmol/L( x±s ) resectively, and were obviously higher than those in normal control. 3)in 21 hypercalcemia patients with prostatic cancer, 61.9% of the patients (13/21)had increased PTHrP (1 86) (with a mean value of 7.4pmol/L,range 2.88～19.1pmol/L). 4)a positive correlation was observed between PSA and PTHrP concentrations in HHM patients with prostatic cancer ( r =0.823, P <0.001) .The results suggest that determination of serum PSA and PTHrP are better indicator for the diagnosis and evaluation of treatment in prostatic cancer.